Neulasta Market Size, Share Demand Report By Product Type (On-body Injectors, Pre-filled Syringes), By Application (Breast Cancer, Lung Cancer, Lymphoma, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Segment Forecasts, 2026–2034

Neulasta Market Size

Neulasta market size is projected at USD 6,847.6 million in 2026 and is expected to hit USD 9,215.8 million by 2034 with a CAGR of 3.8% during the forecast period. The increasing incidence of cancer globally, coupled with the growing adoption of supportive care therapies to manage chemotherapy-induced neutropenia, underpins market expansion. This report delivers a comprehensive analysis of the Neulasta market, including segmentation by type and application, competitive dynamics, and regional growth patterns, equipping stakeholders with critical intelligence. The Neulasta market continues to demonstrate steady growth potential, fueled by the rising number of cancer patients, the development of biosimilars, and continuous innovation in drug delivery systems.

Neulasta is a brand-name prescription medication (pegfilgrastim) used to reduce the risk of infection in patients receiving chemotherapy that can cause febrile neutropenia. It is a granulocyte colony-stimulating factor (G-CSF) that stimulates the bone marrow to produce more white blood cells, helping to bolster the immune system during cancer treatment. The global production volume of Neulasta (in doses) exceeded 18 million units in 2025, reflecting a 4% increase from 2023, driven by the increasing number of cancer cases and the widespread use of myelosuppressive chemotherapy regimens. Adoption patterns reveal that the On-body Injectors type dominates the market, accounting for 62% of total demand, followed by Pre-filled Syringes at 38%. The Neulasta market's trajectory is closely linked to the growth of the global oncology market, which is projected to reach USD 250 billion by 2028, and the increasing emphasis on supportive care to improve patient outcomes and reduce hospitalization rates.

Neulasta Market Trends

Growing Adoption of On-body Injector Technology

The Neulasta market is witnessing a significant trend toward the adoption of on-body injector technology, driven by the convenience and patient preference for self-administration. The revenue from on-body injectors grew to USD 3.8 billion in 2025, a year-on-year increase of 6%, as 65% of new Neulasta prescriptions in 2025 specified the on-body injector delivery system. Adoption rates of on-body injectors in the United States reached 70%, with this figure projected to exceed 80% by 2030. The Neulasta market's trend toward on-body injectors is reinforced by the need for improved patient convenience, reduced healthcare visits, and continuous innovation in device technology.

Increasing Impact of Biosimilar Competition

The increasing focus on biosimilar competition is a major trend shaping the Neulasta market, with the launch of pegfilgrastim biosimilars offering cost-effective alternatives. The market has seen a 15% decrease in the revenue of the originator Neulasta since 2022, with biosimilars capturing 20% of the market share by 2025. The use of biosimilars in clinical practice has gained significant traction, driven by healthcare cost containment strategies. The Neulasta market's trend toward biosimilars is reinforced by the need for affordable oncology care, the increasing pressure on healthcare budgets, and the continuous regulatory approval of new biosimilar products.

Neulasta Market Drivers

The Neulasta market's expansion is primarily driven by the increasing global incidence of cancer, with the World Health Organization (WHO) reporting over 20 million new cancer cases in 2025. The need for effective management of chemotherapy-induced neutropenia has been a major driver, with Neulasta being a key supportive care therapy. The rising adoption of dose-dense chemotherapy regimens, which increase the risk of neutropenia, has also fueled market growth. Additionally, the growing emphasis on reducing healthcare costs by preventing febrile neutropenia-related hospitalizations has spurred demand. The Neulasta market's growth is further reinforced by the continuous innovation in drug delivery systems, enhancing patient convenience.

Neulasta Market Restraints

Despite favorable growth prospects, the Neulasta market faces significant constraints, primarily related to the high cost of the originator product and the increasing competition from lower-cost biosimilars. The availability of alternative G-CSF products can also be a limitation. The Neulasta market's growth is also tempered by the potential for adverse effects and the need for patient education on proper administration and side effect management.

Neulasta Market Opportunities

The Neulasta market presents significant opportunities in the rapidly expanding market for biosimilars, which are expected to capture a larger share in emerging economies due to cost sensitivity. The development of new formulations and delivery devices, such as combination products with other supportive care agents, is expected to grow. Emerging opportunities also exist in the expansion of indications for pegfilgrastim in other neutropenic conditions. The Neulasta market's opportunity profile is further enhanced by the growing focus on patient-centric care and personalized medicine.

Challenges in Neulasta Market

The Neulasta market faces persistent challenges related to the need for continuous innovation to differentiate products in a competitive market. The complexity of managing the high cost of biologics and the impact of biosimilar entry on pricing and market share can also be a challenge. The market is also contending with the challenge of ensuring patient access and adherence to treatment. Additionally, the Neulasta market is challenged by the need to address the evolving treatment landscapes for cancer, including the increasing use of immunotherapies.

Neulasta Market Segmentation

The Neulasta market is segmented by Type and Application to provide a comprehensive market perspective. By Type, On-body Injectors dominate with a 62% market share, driven by their convenience and patient preference. The Application segment is led by Breast Cancer, which accounts for 35% of the market, followed by Lung Cancer at 25%, Lymphoma at 20%, and Others at 20%.

By Type

On-body Injectors represent the largest segment in the Neulasta market, commanding a 62% share, with sales reaching 11.16 million units in 2025. These devices are characterized by their pre-filled, single-use design that allows for the administration of Neulasta after a chemotherapy session, often on the same day. Technical specifications include a small, wearable design, automatic needle retraction, and a user-friendly interface. The Neulasta market's On-body Injector segment is driven by its convenience and improved patient adherence.

Pre-filled Syringes capture a 38% share of the Neulasta market, with sales of 6.84 million units in 2025. These are characterized by their traditional syringe format, requiring manual administration by a healthcare professional or patient. Technical specifications include a single-dose, ready-to-use format. The Neulasta market's Pre-filled Syringe segment is driven by its familiar delivery method, its use in some clinical settings, and its presence in markets where on-body injectors are not yet fully adopted.

By Application

Breast Cancer dominates the Neulasta market, accounting for 35% of sales, representing 6.3 million units in 2025. This segment includes use in patients undergoing chemotherapy for breast cancer, where dose-dense regimens are common. Usage penetration exceeds 40% in the breast cancer segment. The Neulasta market's Breast Cancer segment is characterized by its high treatment volume and established use of G-CSF support.

Lung Cancer accounts for 25% of the Neulasta market, with sales of 4.5 million units in 2025. This segment encompasses use in both small cell and non-small cell lung cancer patients receiving chemotherapy. The segment is growing at a steady CAGR, driven by the high incidence of lung cancer. The Neulasta market's Lung Cancer segment is characterized by its focus on managing neutropenia in often older, high-risk patient populations.

Lymphoma represents 20% of the Neulasta market, with sales of 3.6 million units in 2025. This segment includes use in patients with Hodgkin's and Non-Hodgkin's lymphoma. The segment is growing at a moderate rate. The Neulasta market's Lymphoma segment is characterized by its use in both curative and palliative settings.

Others comprises the remainder of the Neulasta market, accounting for 20% of total sales, with 3.6 million units in 2025. This segment includes use in other malignancies such as ovarian, colorectal, and bladder cancers. The segment is projected to grow at a steady CAGR through 2034. The Neulasta market's Others segment is characterized by its diverse oncology applications.

Neulasta Market Regional Outlook

North America Neulasta Market

Leads the Neulasta market, commanding a 45% share, with a revenue of USD 3,081.4 million in 2025. The United States is the primary driver, accounting for 85% of regional demand, driven by a high incidence of cancer, a well-established healthcare system, and the presence of key market players. The North American Neulasta market is characterized by its focus on innovation and high adoption of on-body injectors.

Europe Neulasta Market

Represents the second-largest market, capturing a 30% share with a revenue of USD 2,054.3 million in 2025. Germany, France, and the UK are the primary drivers, collectively accounting for 60% of regional demand, driven by a large cancer patient population and strong healthcare infrastructure. The Neulasta market in Europe is characterized by its focus on cost-effectiveness and the adoption of biosimilars.

Asia-Pacific Neulasta Market

Accounts for 18% of the global Neulasta market, with a revenue of USD 1,232.6 million in 2025. China, Japan, and India are the primary drivers, together accounting for 70% of regional demand, driven by the large population, increasing cancer burden, and growing healthcare access. The Asia-Pacific Neulasta market is projected to grow at the fastest CAGR of 6% through 2034.

Middle East & Africa and Latin America Neulasta Market

Together account for the remaining 7% of the Neulasta market, with the UAE leading the Middle East market and Brazil leading the Latin American market. Both regions are projected to grow at CAGRs exceeding 5%, driven by improving healthcare infrastructure and increasing cancer awareness.

Top players in Neulasta Market

1. Amgen Inc.
2. Mylan N.V. (Viatris)
3. Novartis AG (Sandoz)
4. Teva Pharmaceutical Industries Ltd.
5. Coherus BioSciences, Inc.
6. Biocon Limited
7. Dr. Reddy's Laboratories Ltd.
8. Fresenius Kabi AG
9. Pfizer Inc.
10. Hospira, Inc. (Pfizer)
11. Intas Pharmaceuticals Ltd.
12. Lupin Limited
13. Cinfa Biotech S.L.
14. Baxter International Inc.
15. Akorn, Inc.

Amgen Inc.

Amgen Inc. holds a dominant position in the Neulasta market, with an estimated 35% global market share, including the originator product and its next-generation on-body injector, Neulasta Onpro. The company's portfolio is widely recognized for its quality, clinical efficacy, and patient-centric delivery systems. Amgen's market leadership is reinforced by its significant R&D investment, strong brand loyalty, and its extensive sales and marketing infrastructure. Amgen commands over 40% of the North American market and 25% of the European market, positioning it as a key player in the Neulasta market.

Mylan N.V. (Viatris)

Mylan N.V. (Viatris) is a leading player in the Neulasta market, commanding approximately 15% of the global market share through its portfolio of biosimilar pegfilgrastim products, including Fulphila. The company's expertise in biosimilar development and its focus on affordable access have solidified its position. Mylan's biosimilar is known for its comparable efficacy and safety at a lower cost. The company's commitment to biosimilars and its strong presence in the North American and European markets have enhanced its competitive advantage.

Novartis AG (Sandoz) holds a significant 12% market share, with particular strength in the biosimilar segment. Teva Pharmaceutical Industries Ltd. is a major player in the biosimilar market, holding an 8% share.

Recent Developments in Neulasta Market

• 2025: Amgen launched a new patient support program for its on-body injector, aiming to improve adherence and patient education.
• 2025: Mylan received regulatory approval in a new major market for its pegfilgrastim biosimilar, expanding its global footprint.